RESULTS	In the pamidronate group , the occurrence of hypercalcemia , severe bone pain , and symptomatic impending fractures decreased by 65 % , 30 % , and 50 % , respectively ; event-rates of systemic treatment and radiotherapy decreased by 35 % ( P < or = .02 ) .\